Research ExplorerPublicationsThe Effect of 10 Most Common Nonurological Primary Cancers o...

The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer

Standard

The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. / Wenzel, Mike; Nocera, Luigi; Würnschimmel, Christoph; Collà Ruvolo, Claudia; Tian, Zhe; Saad, Fred; Briganti, Alberto; Tilki, Derya; Graefen, Markus; Becker, Andreas; Roos, Frederik C; Chun, Felix K H; Karakiewicz, Pierre I.

In: FRONT ONCOL, Vol. 11, 754996, 2021.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Wenzel, M, Nocera, L, Würnschimmel, C, Collà Ruvolo, C, Tian, Z, Saad, F, Briganti, A, Tilki, D, Graefen, M, Becker, A, Roos, FC, Chun, FKH & Karakiewicz, PI 2021, 'The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer', FRONT ONCOL, vol. 11, 754996. https://doi.org/10.3389/fonc.2021.754996

APA

Wenzel, M., Nocera, L., Würnschimmel, C., Collà Ruvolo, C., Tian, Z., Saad, F., Briganti, A., Tilki, D., Graefen, M., Becker, A., Roos, F. C., Chun, F. K. H., & Karakiewicz, P. I. (2021). The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. FRONT ONCOL, 11, [754996]. https://doi.org/10.3389/fonc.2021.754996

Vancouver

Wenzel M, Nocera L, Würnschimmel C, Collà Ruvolo C, Tian Z, Saad F et al. The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. FRONT ONCOL. 2021;11. 754996. https://doi.org/10.3389/fonc.2021.754996

Bibtex

@article{c7eff01d64e14fe9aed0c9142d51aae4,
title = "The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer",
abstract = "Background: This study aims to test the effect of the 10 most common nonurological primary cancers (skin, rectal, colon, lymphoma, leukemia, pancreas, stomach, esophagus, liver, lung) on overall mortality (OM) after secondary prostate cancer (PCa).Material and Methods: Within the Surveillance, Epidemiology, and End Results (SEER) database, patients with 10 most common primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion (age, year at diagnosis, race/ethnicity, treatment type, TNM stage) with primary PCa controls. OM was compared between secondary and primary PCa patients and was stratified according to primary cancer type, as well as according to time interval between primary cancer vs. secondary PCa diagnoses.Results: We identified 24,848 secondary PCa patients (skin, n = 3,871; rectal, n = 798; colon, n = 3,665; lymphoma, n = 2,583; leukemia, n = 1,102; pancreatic, n = 118; stomach, n = 361; esophagus, n = 219; liver, n = 160; lung, n = 1,328) vs. 531,732 primary PCa patients. Secondary PCa characteristics were less favorable than those of primary PCa patients (PSA and grade), and smaller proportions of secondary PCa patients received active treatment. After 1:4 matching, all secondary PCa exhibited worse OM than primary PCa patients. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis and subsequent secondary PCa.Conclusion: Patients with secondary PCa are diagnosed with less favorable PSA and grade. Even after matching for PCa characteristics, secondary PCa patients still exhibit worse survival. However, the survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary cancer diagnosis.",
author = "Mike Wenzel and Luigi Nocera and Christoph W{\"u}rnschimmel and {Coll{\`a} Ruvolo}, Claudia and Zhe Tian and Fred Saad and Alberto Briganti and Derya Tilki and Markus Graefen and Andreas Becker and Roos, {Frederik C} and Chun, {Felix K H} and Karakiewicz, {Pierre I}",
note = "Copyright {\textcopyright} 2021 Wenzel, Nocera, W{\"u}rnschimmel, Coll{\`a} Ruvolo, Tian, Saad, Briganti, Tilki, Graefen, Becker, Roos, Chun and Karakiewicz.",
year = "2021",
doi = "10.3389/fonc.2021.754996",
language = "English",
volume = "11",
journal = "FRONT ONCOL",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

RIS

TY - JOUR

T1 - The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer

AU - Wenzel, Mike

AU - Nocera, Luigi

AU - Würnschimmel, Christoph

AU - Collà Ruvolo, Claudia

AU - Tian, Zhe

AU - Saad, Fred

AU - Briganti, Alberto

AU - Tilki, Derya

AU - Graefen, Markus

AU - Becker, Andreas

AU - Roos, Frederik C

AU - Chun, Felix K H

AU - Karakiewicz, Pierre I

N1 - Copyright © 2021 Wenzel, Nocera, Würnschimmel, Collà Ruvolo, Tian, Saad, Briganti, Tilki, Graefen, Becker, Roos, Chun and Karakiewicz.

PY - 2021

Y1 - 2021

N2 - Background: This study aims to test the effect of the 10 most common nonurological primary cancers (skin, rectal, colon, lymphoma, leukemia, pancreas, stomach, esophagus, liver, lung) on overall mortality (OM) after secondary prostate cancer (PCa).Material and Methods: Within the Surveillance, Epidemiology, and End Results (SEER) database, patients with 10 most common primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion (age, year at diagnosis, race/ethnicity, treatment type, TNM stage) with primary PCa controls. OM was compared between secondary and primary PCa patients and was stratified according to primary cancer type, as well as according to time interval between primary cancer vs. secondary PCa diagnoses.Results: We identified 24,848 secondary PCa patients (skin, n = 3,871; rectal, n = 798; colon, n = 3,665; lymphoma, n = 2,583; leukemia, n = 1,102; pancreatic, n = 118; stomach, n = 361; esophagus, n = 219; liver, n = 160; lung, n = 1,328) vs. 531,732 primary PCa patients. Secondary PCa characteristics were less favorable than those of primary PCa patients (PSA and grade), and smaller proportions of secondary PCa patients received active treatment. After 1:4 matching, all secondary PCa exhibited worse OM than primary PCa patients. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis and subsequent secondary PCa.Conclusion: Patients with secondary PCa are diagnosed with less favorable PSA and grade. Even after matching for PCa characteristics, secondary PCa patients still exhibit worse survival. However, the survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary cancer diagnosis.

AB - Background: This study aims to test the effect of the 10 most common nonurological primary cancers (skin, rectal, colon, lymphoma, leukemia, pancreas, stomach, esophagus, liver, lung) on overall mortality (OM) after secondary prostate cancer (PCa).Material and Methods: Within the Surveillance, Epidemiology, and End Results (SEER) database, patients with 10 most common primary cancers and concomitant secondary PCa (diagnosed 2004-2016) were identified and were matched in 1:4 fashion (age, year at diagnosis, race/ethnicity, treatment type, TNM stage) with primary PCa controls. OM was compared between secondary and primary PCa patients and was stratified according to primary cancer type, as well as according to time interval between primary cancer vs. secondary PCa diagnoses.Results: We identified 24,848 secondary PCa patients (skin, n = 3,871; rectal, n = 798; colon, n = 3,665; lymphoma, n = 2,583; leukemia, n = 1,102; pancreatic, n = 118; stomach, n = 361; esophagus, n = 219; liver, n = 160; lung, n = 1,328) vs. 531,732 primary PCa patients. Secondary PCa characteristics were less favorable than those of primary PCa patients (PSA and grade), and smaller proportions of secondary PCa patients received active treatment. After 1:4 matching, all secondary PCa exhibited worse OM than primary PCa patients. Finally, subgroup analyses showed that the survival disadvantage of secondary PCa patients decreased with longer time interval since primary cancer diagnosis and subsequent secondary PCa.Conclusion: Patients with secondary PCa are diagnosed with less favorable PSA and grade. Even after matching for PCa characteristics, secondary PCa patients still exhibit worse survival. However, the survival disadvantage is attenuated, when secondary PCa diagnosis is made after longer time interval, since primary cancer diagnosis.

U2 - 10.3389/fonc.2021.754996

DO - 10.3389/fonc.2021.754996

M3 - SCORING: Journal article

C2 - 34692543

VL - 11

JO - FRONT ONCOL

JF - FRONT ONCOL

SN - 2234-943X

M1 - 754996

ER -